Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Single-Arm Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Once-Yearly Intramuscular Lenacapavir for HIV Pre-exposure Prophylaxis (PrEP) in People With an Indication for PrEP

NCT07047716 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT07047716
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07047716 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Single-Arm Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Once-Yearly Intramuscular Lenacapavir for HIV Pre-exposure Prophylaxis (PrEP) in People With an Indication for PrEP
Lead sponsor
Gilead Sciences
Phase
Phase 3
Overall status
Active, not recruiting
Start date
July 22, 2025
Completion date
September 30, 2028
Enrollment
339 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

hiv pre-exposure prophylaxis